A clear comparison
Ipamorelin and tesamorelin both relate to growth hormone release, through different receptors. Ipamorelin acts through the ghrelin receptor; tesamorelin is a GHRH analogue.
The differences at a glance
Reference facts and current product information are separate below. On a small screen, swipe within the table; keyboard users can focus it and scroll with the arrow keys.
| Compare | Ipamorelin | Tesamorelin |
|---|---|---|
| Reference · material class | GH secretagogue | GHRH analogue |
| Reference · identity and composition | Ipamorelin. Supplied form and exact specification require matching documentation. | Tesamorelin. Supplied form and exact specification require matching documentation. |
| Reference · research question | Growth hormone signalling | Growth hormone & visceral fat |
| Reference · evidence and limitations | A growth hormone response is a biological measurement. It does not, by itself, establish muscle growth, better sleep, faster recovery or a particular change in body composition. | Visceral fat is fat around internal organs. It is different from total body weight and from the fat under the skin. Findings in people with HIV-associated abdominal fat cannot simply be extended to every weight-management question. |
| Reference · source papers | Raun et al. (1998): ipamorelin pharmacology | Falutz et al. (2007): tesamorelin in people with HIV and abdominal fat accumulation |
| Product · current sizes and prices | 5 mg · $49.99 In stock10 mg · $74.99 In stock | 10 mg · $109.99 In stock20 mg · $179.99 In stock |
| Product · current stock | In stock | In stock |
| Product · supplied specification | Confirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications | Confirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications |
| Product · matching lot records | No matching published record. Check Lab Results | No matching published record. Check Lab Results |
| Product · information and availability | View available options | View available options |
Product figures come from the current WooCommerce listing in the store currency. Package milligrams are nominal material amounts, not doses. No report for another sample or lot is substituted for a matching record.
Two routes into the same hormone system
A growth hormone secretagogue is a compound that stimulates growth hormone release. Ipamorelin is discussed in that context through the ghrelin receptor. Tesamorelin mimics growth hormone-releasing hormone. Sharing a downstream hormone does not make the upstream mechanisms identical, and it does not make their evidence interchangeable.
What people usually want to understand
Common search interests include body composition, muscle growth, visceral fat and recovery. Each needs its own endpoint. A hormone measurement describes a biological response; a body-composition study measures a different outcome. Avoid treating a change in growth hormone as proof of increased muscle or a particular recovery benefit.
Why tesamorelin and visceral fat appear together
The cited tesamorelin trial studied people with HIV and abdominal fat accumulation. Visceral fat refers to fat around internal organs. That is a more specific question than general weight loss. Both the study population and the measured fat compartment matter when deciding what the result can tell you.
How to compare the listings
Start with compound identity and the research question. Then compare live package sizes, prices and exact-SKU documentation. A larger milligram number does not establish greater effectiveness across two different molecules. Package-size comparisons are most useful within the same compound; scientific comparisons require the original study methods.
Common questions
Are ipamorelin and tesamorelin the same peptide?
No. They act through different receptor pathways and have different research evidence.
Does growth hormone research prove muscle growth?
No. A hormone response and measured muscle growth are different outcomes.
Original sources
These papers support the specific mechanisms or study models discussed above. They do not test the current Peptide Place catalogue batches.
- Raun et al. (1998): ipamorelin pharmacology ↗
- Falutz et al. (2007): tesamorelin in people with HIV and abdominal fat accumulation ↗
Continue exploring
Ipamorelin: current options and full overview →

